BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$57.54
arrow_upward
+0.63%(+0.36) 1D
$57.54
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 5, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$57.11
High
$58.11
Low
$56.82
Mkt. cap
11.14B
Avg. vol.
1.93M
Volume
2.41M
P/E ratio
155.12
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
Open
$57.11
High
$58.11
Low
$56.82
Mkt. cap
11.14B
Avg. vol.
1.93M
Volume
2.41M
P/E ratio
155.12
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Investing.com Canada
·
1 hour ago
BioMarin names Cara Bauer as chief people officer By Investing.com
Stock Titan
·
1 hour ago
A new HR chief brings more than 25 years of experience across biotech and tech to BioMarin.
AD HOC NEWS
·
2 hours ago
BioMarin stock gets fresh five-year Pompe data signal
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com